Deutsche Bank Ag\ Contrafect Corp Transaction History

Deutsche Bank Ag\

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 04, 2021	SELL	$3.19 - $4.43 $114 - $159	-36 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$3.58 - $4.9 $62,413 - $85,426	-17,434 Reduced 99.79%	36 $0
Q1 2021 May 13, 2021	SELL	$4.46 - $6.68 $6,636 - $9,939	-1,488 Reduced 7.85%	17,470 $83,000
Q4 2020 Feb 16, 2021	BUY	$5.05 - $6.4 $26,032 - $32,992	5,155 Added 37.35%	18,958 $96,000
Q3 2020 Nov 12, 2020	BUY	$5.05 - $6.99 $38,380 - $53,124	7,600 Added 122.52%	13,803 $73,000
Q2 2020 Aug 13, 2020	BUY	$4.69 - $7.81 $29,092 - $48,445	6,203 New	6,203 $40,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.